Background: There is a considerable gap between randomized clinical trials and implementing the results into practice. This is particularly relevant in the use of broad-spectrum antibiotics in hospitals. Hospital pharmacists can be effective vehicles for bridging this gap and promoting evidence-based medicine. To determine the most effective way of using the pharmacist in this role, a prospective cefotaxime intervention study was conducted with randomization incorporated into the design as well as patient-related therapeutic outcomes. Methods: A total of 323 patients who were prescribed cefotaxime were randomized into an intervention or nonintervention group where only the former was challenged by pharmacists for inappropriate cefotaxime usage relative to hospital guidelines. The primary outcome was the appropriateness of cefotaxime prescribing between groups. Logistic regression analysis was then used to identify factors that were associated with successful clinical response. Results: Overall, 94% of orders in the intervention group met cefotaxime dosage criteria compared with 86% in the control group ( p = .018). However, there was no impact with respect to promoting cefotaxime use for an appropriate indication (81% vs. 80%; p = .67). There was a trend for improved clinical outcomes in patients who received cefotaxime within hospital guidelines (OR = 1.73; p = .31). Conclusions: The pharmacist as a vehicle for promoting the appropriate use of broad-spectrum antibiotics in the acute care hospital setting can improve the dosing of such agents. However, several barriers to optimizing the impact of the pharmacist were implied by the data. Removing these barriers could increase the pharmacists' utility as an agent for improved patient care.
There is a considerable gap between research and implementing the results into clinical practice. This is particularly relevant in the use of antibiotics in the acute care hospital setting that are prescribed for empiric treatment of suspected infections, treatment of proven infections, or as a prophylaxis. Selective pressure due to the overuse of antibiotics is considered to be an important factor in the emergence of antibiotic resistance (5;14) . Consequently, there has been an alarming increase in the prevalence of nosocomial antibiotic-resistant bacteria. This has included the emergence of multiresistant gram-negative bacteria, vancomycin-resistant enterococci (VRE), and methicilline-resistant Staphylococcus aureus (5;11;15) . In a recent multicenter epidemiologic study implemented by the Centers for Disease Control and Prevention in Atlanta, Georgia, the overuse of broad-spectrum antibiotics was definitively identified as a major risk factor in the development of antibiotic resistance (9) . Therefore, mechanisms have to be identified to limit the use of these agents by changing the prescribing behavior of physicians.
There are several methods that have been used to alter drug usage patterns of physicians to comply with evidence-based clinical guidelines. These have included the dissemination of written educational materials, didactic educational sessions, local consensus conferences, audit with prescriber feedback, physician prompting, and educational outreach mechanisms. In their overview of interventions to promote evidence-based medicine, Bero and colleagues (2) concluded that these approaches had variable effectiveness when used alone. Of all the methods reviewed, physician prompting and educational outreach mechanisms appeared to be the most effective approaches to promoting behavior change. The investigators also speculated that a combination of two or more of these methods would have the greater likelihood of success (2) .
In the acute care hospital setting, the clinical pharmacist is an important member of the multidisciplinary team. Their responsibilities include reviewing patient medication profiles, identifying and monitoring adverse drug reactions, dosage recommendations, and patient education. One important role of the pharmacist that has not been uniformly utilized in hospitals around the world is as an agent for promoting evidence-based medicine. Most of the studies that have evaluated the impact of the pharmacist on appropriate drug use have been poorly designed because they lacked randomization, and few had clearly defined clinical and economic endpoints. In one review, Soumerai (16) evaluated the drug use evaluation literature and reported that such intervention studies should be interpreted cautiously because 72% of all evaluated reports used inappropriate methodology and only 3% were randomized.
To address these limitations and to properly evaluate the optimal role of the pharmacist as an agent for promoting evidence-based antibiotic use in the acute care setting, a prospective randomized intervention study was conducted. The intervention in this case was physician prompting and educational outreach by the pharmacist, who acted as an advocate for evidence-based medicine and appropriate drug use. In the author's institutions, antibiotics that are under restricted use can only be prescribed or have to be approved by the infectious disease service. Cefotaxime was chosen as the study drug because it is a costly broad-spectrum cephalosporin that recently had the institutional "restricted use label" removed. Therefore, it became a high-risk candidate for inappropriate prescribing.
METHODS

Patients and Study Design
This study was a 6-month randomized two-center (Toronto General and Toronto Western Hospital) prospective trial consisting of adult patients with infections who required intravenous antibiotic therapy. The unit of measurement in the study was a cefotaxime prescription alone or in combination with another antibiotic. Therefore, patients could be enrolled more than once if cefotaxime was prescribed on two separate occasions.
Eligibility criteria consisted of cefotaxime orders written by physicians who had prescribing privileges at one of the two hospitals. In addition, the order had to be written on units that were serviced by a clinical pharmacist. Cefotaxime prescriptions written as part of an approved study protocol were not eligible for inclusion. Prior to its onset, the study had been approved by the institutional ethics review board, with the condition that the pharmacist contact the physician if the patient would be put at risk without an intervention.
Once eligible patients were identified, they were stratified by hospital and then randomized on a one-to-one basis via a computer-generated list into an intervention (INT) and nonintervention (non-INT) group. The randomization took place in the central pharmacy of each hospital and was done via telephone on a consecutive basis. Once the randomization had taken place, the unit pharmacist was informed as to the cefotaxime prescription's allocation group. Only the unit pharmacist and the central pharmacy were aware of the patient's treatment allocation. All other medical unit personnel were blinded to the status of the patient. Regardless of study group, the clinical pharmacist, in conjunction with the attending physician, was responsible for the care of all patients.
Description of Maneuvers and Study Outcomes
Following the randomization process, the clinical pharmacist recorded the patient history, risk factors for infection, diagnosis, and other clinical characteristics. For the associated cefotaxime order, the pharmacist also recorded the indication for use, dosage, the status of the prescriber (e.g., resident, staff physician, etc.), and the type of nursing unit (e.g., general medicine, intensive care unit, etc.). Following this, the unit pharmacist reviewed the cefotaxime order to determine if it was consistent with institutional guidelines (both hospitals had the same guidelines following an institutional merger). The guidelines were developed by an expert antibiotic subcommittee of the Pharmacy and Therapeutics Committee using a systematic literature review process (Appendix 1). All study pharmacists were trained at the baccalaureate level, but few had advanced clinical degrees.
For cefotaxime orders that were contrary to institutional usage criteria, only physicians whose prescriptions were randomized into the INT arm were contacted for therapeutic modification. The objective of the intervention was to recommend an alternative antibiotic to cefotaxime when indicated or to ensure that the appropriate dose of cefotaxime was being prescribed. The contact was in the form of a verbal reminder, which was followed by a faceto-face educational outreach initiative among physicians who had not modified therapy. Educational outreach is analogous to detailing performed by the pharmaceutical industry. However, in this case the person performing the detailing did not have a commercial interest in the product. The objective of the educational initiative was to review the guidelines with the prescriber and offer alternative antibiotics. Cefotaxime orders in the non-INT group were also evaluated for appropriateness, but there was no pharmacist-physician interaction. Pharmacists only intervened on inappropriate orders in the intervention arm. Patients in both groups were then followed and the clinical outcome of cefotaxime therapy was documented.
The primary outcome in this investigation was the proportion of cefotaxime orders in the INT and non-INT group that were consistent with hospital guidelines. The prescriptions from each group were classified as meeting cefotaxime guidelines with respect to indication and dosage. If the order met both indication and dosage criteria, it was classified as having "met all" of the hospital prescribing requirements.
The clinical response was assessed at the end of the cefotaxime course of therapy as recorded in the patient's chart. A successful clinical response was defined as a resolution of all signs and symptoms of infections without treatment modification. In addition, a success was also recorded if the patient was switched to an oral antibiotic because of an adequate response to intravenous antibiotic therapy. Failure of cefotaxime therapy occurred if the signs and symptoms remained the same or worsened, requiring an addition or a change to a new antibiotic, the patient died secondary to the infectious complication, or the patient was withdrawn from cefotaxime because of side effects. Patients who died within the first 24 hours after the cefotaxime was started or transferred to another hospital were classified as being unevaluable. Other study outcomes recorded were the duration of cefotaxime therapy, the mean cost per course of therapy, and cost savings associated with successful pharmacist interventions.
Sample Size and Statistical Analysis
This study was designed to compare the two cefotaxime groups with the hypothesis that a higher proportion of cefotaxime orders would be within hospital guidelines in the intervention group. Inappropriate antibiotic prescribing has been shown to be as high as 40% (17) . By assuming an alpha of 5% (two-tailed), power of 80%, probability of appropriate prescribing with and without the intervention at 75% and 60% (absolute difference = 15%), respectively, the case sample size for the uncorrected chi-square test in this randomized study was 300, which was then increased by 10% to account for patient dropouts.
The primary outcome was the proportion of cefotaxime orders meeting hospital guidelines. The chi-square statistic was used to test the significance of this difference between the intervention and nonintervention groups. Parametric and nonparametric inferential statistics were used to compare differences in the duration of cefotaxime therapy between groups as well as overall treatment cost. The cut-off for significance for all of these procedures was p = .05.
To determine which factors were associated with improved cefotaxime guideline compliance, a multivariable logistic regression analysis was conducted. The dependent variable in the model was guideline compliance (yes/no). A second logistic regression analysis was performed to measure the impact of appropriate cefotaxime prescribing on clinically successful therapy. In this latter analysis, the dependent variable in the model was clinical response (yes/no) as defined in the study protocol. Before the final models were developed, the relevant covariates for model inclusion were identified by a bivariate screening process using a 2-by-2 table with a preset alpha = 0.15. This is a recommended approach for removing unimportant covariates so that a more manageable set of variables can be submitted to multivariate techniques (10) . Categories were collapsed in cases where the number of observations within cells was less than 10. All of the statistical analyses were performed using Stata release 6.0.
RESULTS
A total of 332 patients receiving cefotaxime were entered into the study. Of these, 13 randomized into the non-INT group had pharmacists' interventions and were excluded because the patient would have been put at risk without contacting the physician. Another six were excluded because pharmacists had made a suggestion to initiate cefotaxime before the order was written and four others because they were written on units that were not serviced by clinical pharmacists. Hence, the final number of patients receiving cefotaxime that completed the study was 309.
Overall, 147 and 162 patients were randomized into the non-INT and INT groups, respectively. Patient groups were reasonably well distributed with respect to age, gender, hospital site, previous antibiotic therapy, and primary site of infection. However, some imbalance was evident with respect to underlying disease, risk factors for infection, and diagnosis (Table 1) . With respect to the characteristics of the actual cefotaxime order, there was good balance in the medical unit of origin, status of prescribing physician, and median cefotaxime dosage ( Table 2 ). The proportion of cefotaxime orders meeting indication and dosage criteria were then assessed (Table 3) . Overall, 80% of orders in the non-INT group were for an appropriate indication compared with 81% in the INT group ( p = .67). In contrast, an appropriate cefotaxime dosage was used in 94% of cefotaxime orders that were written in collaboration with unit pharmacists compared with only 86% in the control group ( p = .018). The final assessment of each cefotaxime prescription demonstrated that both prescribing criteria (indication and dosage) were met in 75% of orders in the INT group compared with only 69% in the control group, but the difference failed to reach statistical significance ( p = .24). Overall, pharmacists performed 63 interventions and had a success rate of 81%. However, only eight of these successful interventions were for an appropriate indication. The remainder that were accepted were for dosage modification.
The median duration of therapy in the INT group was 4.3 days compared with 4.8 days in the control group ( p = .28). This translated to a mean cost per treatment course of $198 and $245 in the INT and non-INT groups, respectively ( p = .32). Overall, there was less cefotaxime used in the intervention group over the entire study period, which translated to a savings of approximately $3,000. 
12%
Abbreviations: Dependent variable = prescribing within hospital guidelines (yes/no); renal insufficiency = patient had renal insufficiency (yes/no); immunosuppression = patient was receiving immunosuppressive therapy (yes/no); model R 2 H = percentage of variability in the dependent variable that was accounted for by the model.
When the data were subjected to multivariable logistic regression analysis with cefotaxime use within guidelines (yes/no) as the dependent variable, some interesting findings were identified. As was suggested in the univariate analysis (Table 3) , there was a trend for improved cefotaxime prescribing when educational interventions were performed by pharmacists (Table 4) . Staff physicians were almost five times more likely (OR = 4.86; p = .012) to use the drug within guidelines compared with residents. In addition, patients with renal insufficiency and those who were concomitantly receiving immunosuppressive therapy were also more likely to received cefotaxime for an appropriate indication and with the correct dosage. Other factors that were positively associated with the correct use of the drug were patient age and duration of therapy (Table 4) .
From the original sample of 309 patients, clinical response to cefotaxime therapy was collected in 196 patients. Clinical outcomes were not obtained in 113 patients because of loss to follow-up or because they were not evaluable for clinical response for the following reasons: death within 24 hours of cefotaxime therapy, death due to other complications, or response inaccessible due to the use of multiple antibiotics. However, the proportion of these 113 patients in which clinical outcomes data were not collected was comparable between the INT and non-INT groups (52.7% vs. 47.3%; p = .98). Therefore, it is unlikely that selection bias occurred.
A multivariable logistic regression analysis was conducted on this subsample with clinical response (yes/no) as the dependent variable. Even though this was a subgroup of the original sample, there were three variables that presented with statistically significant findings. There was an interesting trend in that 117 of 140 patients (83.6%) who had received the drug within hospital guidelines had a documented clinical response compared with 41 of 55 (74.5%) who received cefotaxime outside of guidelines (OR = 1.73; p = .31). There was a positive association between duration of cefotaxime therapy and response where patients who received the drug for a longer period of time were more likely to have a positive outcome to treatment (OR = 1.19; p = .029). In contrast, patients who had been receiving immunosuppressive therapy were less likely to have a response to cefotaxime for their infection (OR = 0.23; p = .013).
DISCUSSION
In North America, 25% to 30% of hospitalized patients receive antibiotic therapy, accounting for up to 50% of total drug expenditures (1;3;6). Moreover, the use of antibiotics in acute care hospitals is frequently suboptimal (7;8). In many instances, antibiotics are administered without appropriate clinical justification, and when their use is indicated, broad-spectrum agents are often used when antimicrobials with a narrower spectrum of activity would suffice. In addition to being costly, such inappropriate use may contribute to the increasing incidence of bacterial resistance in hospitalized patients (9;15) . Prior use of broad-spectrum cephalosporins and vancomycin, for example, have been associated with hospital outbreaks of multi-resistant Enterobacteriaciae and enterococci (4;12). Consequently, there is a need to modify the antibiotic prescribing behavior of physicians to be consistent with evidencebased antibiotic guidelines.
In their systematic review of the literature, Bero and colleagues (2) identified several interventions that have been used to promote behavior change among health professionals. The investigators concluded that the most consistently effective interventions were educational outreach visits, which are analogous to detailing by the pharmaceutical industry but without a commercial interest in the product, prompting, and interactive educational meetings. In particular, the evidence suggests that multifaceted initiatives (which consist of two or more interventions) appear to be more effective than single interventions (2;13). Bero et al. (2) concluded that greater emphasis should be given to conducting studies that evaluate two or more interventions in a specific clinical setting.
The current study was designed to evaluate a multifaceted approach consisting of prompting and educational outreach as the mechanisms to promote the use of broadspectrum antibiotics within a set of institutional guidelines. The instrument for promoting change was the clinical pharmacist. The trial was powered to detect a 15% improvement in the appropriate use of cefotaxime in the intervention group, which consisted of pharmacist prompting and educating physicians on the appropriate use of the drug.
Pharmacists were only able to improve the appropriateness of cefotaxime usage by 6%, and the increase was not statistically significant. Furthermore, their impact was minimal on using cefotaxime for inappropriate indications. These findings may have been due in part to the bias that was introduced against the INT group, where 13 cases in the control group required the pharmacist to act because patient safety was at risk. However, even if these 13 cases were added to the denominator of the non-INT group, the difference would remain non-significant. The only aspect of the cefotaxime order the pharmacist was able to significantly improve was drug dosage.
It is important to offer a hypothesis as to why the pharmacist had only a modest impact on changing the antibiotic prescribing behavior of physicians in the current study. The institutional structure, which gives physicians their autonomy in hospitals, could have acted as a barrier to allowing the pharmacist to effectively promote change. Hence, challenging a physician on antibiotic dosing threatens this autonomy to a lesser degree than would the same intervention on indication for use. There could also have been an educational gap with some of the study pharmacists because, unlike some comparable U.S. centers, there is no institutional policy that requires unit pharmacists to have advanced clinical degrees. As a final point, it is also possible that cefotaxime may not have been the optimal drug for evaluating methods of behavior change because it has been used in the hospital setting for over 10 years and "old habits are hard to break."
The current randomized intervention trial did reveal some important findings. Medical residents were less likely to use cefotaxime appropriately than staff physicians. Since residents are writing the bulk of antibiotic orders in many hospitals, there is a definite need for continuing education on the use of antibiotics in the acute care setting. The intervention literature suggests that an interactive educational workshop may be the best approach to meeting this need as opposed to a formal didactic session or the distribution of written educational material (2;13). It was also reassuring that high-risk patients such as those with renal insufficiency and on immunosuppresant medication were more likely to receive appropriate antibiotic therapy. From an economic perspective, there was a $3,000 net savings in drug cost in the INT group.
The final finding that warrants discussion was the association between cefotaxime use within evidence-based guidelines and response to therapy. The data implied that using an antibiotic within guidelines may improve or at least not compromise the likelihood of a clinical response. In the case of broad-spectrum antibiotics such as cefotaxime, such an outcome is important because most hospital-derived antibiotics guidelines are designed to use less costly, narrower spectrum agents as alternatives to drugs such as cefotaxime. However, these findings should be viewed as hypothesis generating because response was not the primary outcome and was measured in only a subset of the original sample. Notwithstanding, they do have important implications with respect to promoting evidence-based medicine because they suggest that broad-spectrum antibiotic usage in hospitals can be reduced without compromising and possibly improving the quality of patient care. Studies are urgently needed to test this hypothesis so that a new precedent for the promotion of evidence-based practice guidelines can be established.
There are a number of limitations in this study that have to be reviewed. A total of 332 patients were randomized. Of these, 23 were excluded from the study for various reasons. The exclusion of these 23 patients could have compromised the value of the randomization process. However, the application of multivariable analysis adjusted for this potential bias. Another drawback to the study was due to the fact that clinical response data were available in only 196 of 309 patients. It is possible that the response data in this patient subgroup may not represent the entire study sample. However, a comparison of patients between the INT and non-INT groups revealed that clinical response was available in a similar proportion of patients. A final bias in the current study is related to the fact that clinical pharmacists collected all aspects of the data, as opposed to a blinded third party. Unfortunately, funding limitations did not allow the investigators to hire blinded data collection personnel.
In conclusion, the results of the current study revealed that the pharmacist can improve the dosing of broad-spectrum antibiotics and can reduce the use of these agents to some extent. However, there are several potential barriers against optimizing the impact of the pharmacist in the acute care setting. These barriers could be a combination of physician autonomy and limitations in the clinical training of pharmacists. One possible solution to this dilemma would be to improve the clinical training of hospital pharmacists in the area of infectious disease, which would facilitate a closer collaboration with physicians, particularly junior medical staff who write the bulk of antibiotic orders in most acute care hospitals. Such an approach would be an important step in improving the overall use of broad-spectrum antibiotics and curtailing the development of resistant micro-organisms.
POLICY IMPLICATIONS
Hospital Pharmacy Departments should be encouraged to require that all staff pharmacists working in the acute care setting have advanced training in infectious diseases and the clinical use of antibiotics. Individual acute care hospitals should support interactive continuing education programs for junior medical staff on the appropriate use of antibiotics in the acute care setting. Finally, individual acute care hospitals should develop and implement evidence-based guidelines on the appropriate use of broad-spectrum antibiotics in the acute care setting. A clinical pharmacist with experience in infectious diseases would be an effective vehicle for meeting these objectives.
